Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Jun 2026 to Mar 4, 2026v2
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rigel Pharmaceuticals
5 trials monitored
See all monitored trials
Lung Cancer
4,822 trials monitored
See 267 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,101 trials monitored
See 174 trials at risk
Head & Neck Cancer
2,621 trials monitored
See 150 trials at risk
and 1 more disease
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
Trial Details
NCT Number NCT07704658
Lead Sponsor Rigel Pharmaceuticals
Conditions
(from sponsor)		 NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies
Related terms Carcinoma, Non-Small-Cell Lung, Neoplasms, Thyroid Neoplasms
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov